Summit Therapeutics SMMT Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's other accrued liabilities?
- Summit Therapeutics (SMMT) reported other accrued liabilities of $1.15M in Q1 2026.
- How has Summit Therapeutics's other accrued liabilities changed year-over-year?
- Summit Therapeutics's other accrued liabilities increased by 51.3% year-over-year, from $759K to $1.15M.
- What is the long-term trend for Summit Therapeutics's other accrued liabilities?
- Over 5 years (2020 to 2025), Summit Therapeutics's other accrued liabilities has grown at a 25.6% compound annual growth rate (CAGR), from $729K to $2.28M.